A
Menu
April 16, 2020 editorial Open access

Potential for developing a SARS-CoV receptor-binding domain (RBD) recombinant protein as a heterologous human vaccine against coronavirus infectious disease (COVID)-19

Human Vaccines & Immunotherapeutics

DOI: 10.1080/21645515.2020.1740560 Full text (OA) OpenAlex

Authors 0

  1. Author list not loaded yet.

Cited by 4 stored of 139

4 results

References 0